

Freedom of Information Act 2000 - Request Reference FoI/22/468

Wet AMD

- 1. Is bevacizumab (Avastin®) available for use in the treatment of wet age-related macular degeneration (AMD) in your health board (and/or in relation to any other eye conditions). This is an unlicensed use of the drug. In 2018, the then Health Minister said its use for wet AMD in Wales would be a decision for health boards (see attached statement).**

Cardiff and Vale University Health Board can inform you that Bevacizumab has not been used to treat Wet AMD.

- 2. If bevacizumab was available in your health for this use (and/or in relation to any other eye conditions) but this is no longer the case, please could you provide details of the date it ceased to be available and reasons behind this decision.**

Bevacizumab is not used for wet AMD.